Covid19 : AstraZeneca shows better antibody response against Omicron after 3rd shot
AstraZeneca said on Thursday preliminary data from a trial it conducted on its Covid19 shot, Vaxzevria, showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose.
A separate analysis of samples from the trial showed increased antibody response to the Omicron variant. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine. “Vaxzevria has protected hundreds of millions of people from Covid19 around the world and these data show that it has an important role to play as a third dose booster, including when used after other vaccines,” said Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
The company said it is submitting this additional data to health authorities around the world given the urgent need for third dose boosters.